Krystal Biotech Inc

NASDAQ:KRYSUnited States

Today

Show headlines and story abstract

• Krystal Biotech's Q3 Net Income Falls, Revenue Rises, from 7 hours ago by MT Newswires

  7 hours ago by MT Newswires
  Companies Mentioned: KRYS
  08:34 AM EST, 11/04/2024 (MT Newswires) -- Krystal Biotech (KRYS) reported Q3 net income Monday of $0.91 per diluted share, down from $2.79 a year earlier. Analysts polled by Capital IQ expected $0.90. Net revenue for the quarter ended Sept. 30 was ...

• -- Earnings Flash (KRYS) KRYSTAL BIOTECH Reports Q3 Revenue $83.8M, from 8 hours ago by MT Newswires

  8 hours ago by MT Newswires
  Companies Mentioned: KRYS
  08:01 AM EST, 11/04/2024 (MT Newswires) -- ...

• Press Release: Krystal Biotech Announces Third Quarter 2024 Financial Results and Provides Business Updates, from 8 hours ago by Dow Jones

  8 hours ago by Dow Jones
  Companies Mentioned: KRYS

• Krystal Biotech Announces Third Quarter 2024 Financial Results and Provides Business Updates, from 8 hours ago by Dow Jones

  8 hours ago by Dow Jones
  Companies Mentioned: KRYS
  
  This press release includes forward-looking combined R&D and SG&A expense guidance that is not required by, or presented in accordance with, U.S. GAAP and should not be considered as an alternative to R&D and SG&A expense or any other performance measure derived in accordance with GAAP. The Company defines non-GAAP combined R&D and SG&A expense as GAAP combined R&D and SG&A expense excluding stock-based compensation. The Company cautions investors that amounts presented in accordance with its definition of non-GAAP combined R&D and SG&A expense may not be comparable to similar measures disclosed by competitors because not all companies calculate this non-GAAP financial measure in the same manner. The Company presents this non-GAAP financial measure because it considers this measure to be an important supplemental measure and believes it is frequently used by securities analysts, investors, and other interested parties in the evaluation of companies in the Company's industry. Management believes that investors' understanding of the Company's performance is enhanced by including this forward-looking non-GAAP financial measure as a reasonable basis for comparing the Company's ongoing results of operations. Management uses this non-GAAP financial measure for planning purposes, including the preparation of the Company's internal annual operating budget and financial projections; to evaluate the performance and effectiveness of the Company's operational strategies; and to evaluate the Company's capacity to expand its business. This non-GAAP financial measure has limitations as an analytical tool, and should not be considered in isolation, or as an alternative to, or a substitute for R&D and SG&A expense or other financial statement data presented in accordance with GAAP in the Company's consolidated financial statements. The Company has not provided a quantitative reconciliation of forecasted non-GAAP combined R&D and SG&A expense to forecasted GAAP combined R&D and SG&A expense because the Company is unable, without making unreasonable efforts, to calculate the reconciling item, stock-based compensation expenses, with confidence. This item, which could materially affect the computation of forward-looking GAAP combined R&D and SG&A expense, is inherently uncertain and depends on various factors, some of which are outside of the Company's control.